Статті в журналах з теми "AutoBoT"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: AutoBoT.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "AutoBoT".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Holowiecki, Jerzy, Sebastian Grosicki, Andrzej Hellmann, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Anna Dmoszynska, Bozena Marianska, et al. "Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia." Blood 104, no. 11 (November 16, 2004): 5198. http://dx.doi.org/10.1182/blood.v104.11.5198.5198.
Повний текст джерелаАнотація:
Abstract In the previous study by the Polish Adult Leukemia Group (PALG 1999 Study) we demonstrated that addition of cladribine to standard daunorubicine + cytarabine (DA-7) induction potentiates antileukemic activity of the regimen in acute myeloid leukemia (AML). However, there is a concern that the treatment with purine analogues may affect a successful collection of hematopoietic cells for transplantation (autoHCT). The goal of this study was to compare the efficacy of peripheral blood and bone marrow hematopoietic CD34+ cell harvest in patients who both in induction and consolidation were treated with or without purine analogues and who were intended for autoHCT. Sixty-seven AML patients, aged 41 (17–58) years, were included in this study; 33 patients received cladribine-containing regimen (DAC-7), one patient - fludarabine-containing regimen (DAF-7), 33 patients received standard treatment (DA-7, HAM, HD cytarabine). In the DAC-7 treated patients cladribine was also given as a adjunct to second HD cytarabine consolidation. AutoHCT using bone marrow (autoBMT) or peripheral blood (autoBCT) as a source of hematopoietic cells was performed in first complete remission after completion of consolidation therapy. An additional course of AraC 2x2g/m2 on days 1, 3, 5 + G-CSF 10 mg/kg since day 7 was used as mobilization in case of autoBCT. The number of collected CD34+cells/kg was similar for patients pre-traeted with purine analogues and those not receiving purine analogues: 2.55 (0,79-9,25) x106/kg vs 2.5 (1,41–23,5) x106/kg (p=NS) for peripheral blood and 1.62 (0,32–3,01) x106/kg vs 1.55 (0,5–2,45) x106/kg (p=NS) for bone marrow, respectively. In 90% and 95% of patients for both subgroups sufficient number of hematopoietic cells for transplantation could not be collected (p=NS). The proportion of unsuccessful bone marrow harvest was significantly lower for patients pre-treated purine analogues with purine analogues compared to those not receiving purine analogues (90% vs 56%, p=0,04), wheras not difference was found with respect to peripheral blood cell collection (95% vs 62%, p=NS). All patients who received autoHCT engrafted. The time to neutrophil and platelet recovery was similar for both study subgroups. We conclude that treatment with purine analogues in course of induction/consolidation therapy does not impair the hematopoietic cell harvest and does not decrease a chance to perform autoBCT or autoBMT in AML patients.
2
Škrlj, Blaž, Matej Martinc, Nada Lavrač, and Senja Pollak. "autoBOT: evolving neuro-symbolic representations for explainable low resource text classification." Machine Learning 110, no. 5 (April 14, 2021): 989–1028. http://dx.doi.org/10.1007/s10994-021-05968-x.
Повний текст джерелаАнотація:
AbstractLearning from texts has been widely adopted throughout industry and science. While state-of-the-art neural language models have shown very promising results for text classification, they are expensive to (pre-)train, require large amounts of data and tuning of hundreds of millions or more parameters. This paper explores how automatically evolved text representations can serve as a basis for explainable, low-resource branch of models with competitive performance that are subject to automated hyperparameter tuning. We present autoBOT (automatic Bags-Of-Tokens), an autoML approach suitable for low resource learning scenarios, where both the hardware and the amount of data required for training are limited. The proposed approach consists of an evolutionary algorithm that jointly optimizes various sparse representations of a given text (including word, subword, POS tag, keyword-based, knowledge graph-based and relational features) and two types of document embeddings (non-sparse representations). The key idea of autoBOT is that, instead of evolving at the learner level, evolution is conducted at the representation level. The proposed method offers competitive classification performance on fourteen real-world classification tasks when compared against a competitive autoML approach that evolves ensemble models, as well as state-of-the-art neural language models such as BERT and RoBERTa. Moreover, the approach is explainable, as the importance of the parts of the input space is part of the final solution yielded by the proposed optimization procedure, offering potential for meta-transfer learning.
3
Varshney, Prateeksha, and Yogesh Simmhan. "AutoBoT: Resilient and Cost-Effective Scheduling of a Bag of Tasks on Spot VMs." IEEE Transactions on Parallel and Distributed Systems 30, no. 7 (July 1, 2019): 1512–27. http://dx.doi.org/10.1109/tpds.2018.2889851.
Повний текст джерела
4
Joshi, Prayansh Shsank. "Autonomous Stair Climbing Robot." International Journal for Research in Applied Science and Engineering Technology 9, no. VII (July 25, 2021): 2188–203. http://dx.doi.org/10.22214/ijraset.2021.36816.
Повний текст джерелаАнотація:
An autonomous robot, also known as simply an autorobot or autobot, is a robot that performs behaviors or tasks with a high degree of autonomy. Autonomous robotics is usually considered to be a subfield of artificial intelligence, robotics, and information engineering. Specifically, “autonomous robots can help: Increase efficiency and productivity. Reduce error, re-work, and risk rates. Improve safety for employees in high-risk work”environments. In this COVID era every 4 out of the 5 Fortune 500 e-commerce companies and especially the e-commerce giants like Walmart , Amazon and Flipkart are focusing even more on contact less delivery. Delivery using automated bots is a concept that can be used even after the Covid situation gets over. The popularity of e-commerce buying is exploding, and the phenomenon has huge implications for shippers and distributors. To paraphrase Charles Darwin, “those companies best prepared to adapt to this new reality are the ones that will flourish while laggards will be left in the dust”. “Logistics is all about movement from one place to another. This movement happens across facilities and within facilities. While AGVs (AUTOMATED GUIDED VEHICLES) have found their way into applications of material movement inside a warehouse, they are designed to move across flat surfaces with minor undulations (in some cases requiring specialised mezzanine surfaces). This paper comes up with conceptual building and designing an autonomous robot which can work on flat surfaces and even climb up and down standard stairs with a payload of 3-5kg. This paper further will inform you about the conceptual building of an autonomous stair climbing robot involving all the steps like sensor fusion , navigation , tracking , mapping and path planning.
5
Li, Jingyu, Feifan Jin, Renfei Wang, Xiaodan Shang, Peiran Yang, Yuchi Zhu, James K. H. Tsoi, Ki Chan, and Shuhua Wang. "Guided Bone Regeneration in a Periodontally Compromised Individual with Autogenous Tooth Bone Graft: A Radiomics Analysis." Journal of Functional Biomaterials 14, no. 4 (April 14, 2023): 220. http://dx.doi.org/10.3390/jfb14040220.
Повний текст джерелаАнотація:
Background: Autogenous tooth bone graft material (AutoBT) has been advocated as a bone substitute when conducting alveolar ridge preservation. This study is aimed at using a radiomics approach in order to evaluate and testify whether AutoBT can stimulate bone growth during socket preservation in severe periodontal cases. Materials and Methods: For this study, 25 cases with severe periodontal diseases were selected. The patients’ AutoBTs were inserted into the extraction sockets and covered with Bio-Gide® collagen membranes. 3D CBCT scans and 2D X-rays were taken of the patients before surgery and after 6 months post-surgery. For the retrospective radiomics analysis, the maxillary and mandibular images were compared in different groups. Maxillary bone height was analyzed at the buccal, middle, and palatal crest sites, while the mandibular bone height was compared at the buccal, center, and lingual crest sites. Results: In the maxilla, the alveolar height was increased by −2.15 ± 2.90 mm at the buccal crest; −2.45 ± 2.36 mm at the center of the socket, and −1.62 ± 3.19 mm at the palatal crest, while the height of the buccal crest was increased by 0.19 ± 3.52 mm, and the height at the center of the socket was increased by −0.70 ± 2.71 mm in the mandible. The three-dimensional radiomics analysis demonstrated significant bone growth in the local alveolar height and high density. Conclusion: Based on clinical radiomics analysis, AutoBT could be used as an alternative bone material in socket preservation after tooth extraction in patients with severe periodontitis.
6
Stella-Holowiecka, Beata M., Krystyna Jagoda, Aleksandra M. Holowiecka-Goral, Tomasz Czerw, Sebastian Giebel, Malgorzata Krawczyk-Kulis, and Jerzy Holowiecki. "Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia." Blood 104, no. 11 (November 16, 2004): 4439. http://dx.doi.org/10.1182/blood.v104.11.4439.4439.
Повний текст джерелаАнотація:
Abstract For high-risk adult ALL patients alloHCT is a preferable option. However, a significant proportion of those not having a suitable donor may be successfully treated with autotransplantation (autoHCT). Based on our experience this treatment ensures low transplant related mortality below 3% and a reasonable overall survival and disease free survival of 60% and 45% respectively. The status of the disease before transplantation is an important factor for long term results. In childhood ALL most studies suggest that the level of minimal residual disease (MRD) after induction evaluated immunophenotypically or with bio-molecular methods is predictive for outcome after different treatments including chemotherapy, alloHCT and autoHCT. The results in adult ALL are more controversial. Patients selection. Among 1205 haematopoetic cell transplantations performed in our institution 224 (147 autologous, 77 allogeneic) were performed in 205 adults with ALL. For this study we selected an uniform group of 81 patients fulfilling following criteria’s: Ph (-) ALL, status CR1, evaluable MRD, strictly defined autoBMT procedure performed until the end of 2003. Methods. MRD was tested before autoBMT (median interval 10 days) using 2 ore 3-color flow-cytometry, as appropriate. The atypical immunophenotypes were evaluated using the “quadrans” analysis in all cases and since 2002 also the “empty spaces” technique. The sensitivity equals at least 0.0001. For all autoHSCT bone marrow was used as a source of stem cells. The CAV conditioning regimen consisted of cyclophosphamide 60mg/kg on d. -3, -2, cytarabine 2 g/m2 d. -3, -2, -1, etoposide 800 mg/m2 d. -3, -2. Bone marrow was not cryo-preserved after collection but stored in 40 C and re-transplanted after 72h. Results. In 41 patients; age med. 26 y (15–53), F/M=12/29, the MRD level was <0,001: the MRD (−) group. In 40 patients; age med. 29 y (16–53), F/M=18/22, the MRD was detected at the level =/> 0,001; MRD+ group. The ALL-immunophenotypes of MRD−/MRD+ groups were as follows; proB 4/7, preB 2/6, Common 18/19, B 0/1, preT 5/2, T 12/1). The interval from DGN to BMT was similar in both groups. The probability of LFS and OS at 10y calculated with median follow up time of 5y equaled; in the MRD(−) group 47% and 62% and in the MRD+ one 48% and 57% respectively (p=ns). The main reason of failure in both groups was a relapse which occurred after a median time of 277 days in the MRD(−) group and 134 days in MRD+ one (p=0.19). Conclusion and comment. Based on this observation we conclude that a single evaluation stratifying patients before autoBMT according to MRD level below or above 0.001 is not predictive for DFS and OS, because it informs only about the current amount of the disease but not about its opportunistic nature. In this respect a repeatedly confirmed MRD positivity should be more significant. Taking into consideration that the main reason of failures were relapses, this finding suggests also that in patients with chemotherapy-responsive ALL confirmed by stabile CR, the myeloablative CAV regimen is sufficiently strong to eliminate the residual disease at the level ranging 0.01–0.001. It may be speculated only that the 72h lasting incubation of bone marrow product before re-transplantation has also some kind of purging effect for leukemic blasts.
7
Shumway, R. H. "AUTOBOX (Version 1.02)." American Statistician 40, no. 4 (November 1986): 299. http://dx.doi.org/10.2307/2684609.
Повний текст джерела
8
Reilly, David. "The AUTOBOX system." International Journal of Forecasting 16, no. 4 (October 2000): 531–33. http://dx.doi.org/10.1016/s0169-2070(00)00085-6.
Повний текст джерела
9
Bewley, Ronald. "Autobox: A review." Journal of Applied Econometrics 3, no. 3 (July 1988): 240–44. http://dx.doi.org/10.1002/jae.3950030308.
Повний текст джерела
10
Pituskin, Edith, Nanette Cox-Kennett, Harald Becher, Irwindeep Sandhu, Chris Venner, and Ian Paterson. "Cardio-oncology interventions in outpatients referred for autologous bone marrow transplantation." Journal of Clinical Oncology 34, no. 3_suppl (January 20, 2016): 137. http://dx.doi.org/10.1200/jco.2016.34.3_suppl.137.
Повний текст джерелаАнотація:
137 Background: Cancer patients (PTS) referred for autologous bone marrow transplantation (autoBMT) are frequently pre-treated with established cardiotoxins and as a result may not have adequate cardiac function to meet eligibility criteria for autoBMT. Furthermore, mobilizing and consolidation chemotherapy result in additional serial exposures with acute and long-term negative cardiac sequelae. Accordingly, these PTS represent a population with a major unmet need for appropriate cardiovascular screening and interventions. Aim: to evaluate the need and effectiveness of prospective multidisciplinary cardio-oncology assessment and intervention in an unselected outpatient population referred for autoBMT. Methods: From January 1, 2013 – December 31, 2013, PTS referred for autoBMT were systematically screened for comorbid conditions, cardiovascular risk factors and eligibility for transplant. Physical exam, laboratory (ECG, complete profile) and transthoracic echocardiogram with contrast were performed. Those with EF < 50%, increased IVsd/LVpWd, ECG abnormalities +/- significant cardiac history underwent proBNP and high sensitivity troponin testing. PTS with abnormal findings or decreased left ventricular (LV) function were referred to the Edmonton Cardio-Oncology REsearch (ENCORE) program. Results: 73 unique PTS were screened by the Edmonton autoBMT program. Of these, 16 (20%) were reviewed by ENCORE. Reasons for referral included: decreased LV function (n = 6, 38%); increased IVsd (n = 5, 31%); arrhythmia (n = 4, 25%); angina (n = 1, 5%). Pharmacotherapy was initiated for 6 PTS; additional modality or serial cardiac imaging for 12 PTS; urgent stent for 1 PT. 100% proceeded to autoBMT without adverse cardiovascular outcomes or mortality. Conclusions: With systematic screening, a high proportion of PTS referred for autoBMT required cardio-oncology assessment and interventions, with 100% proceeding safely as a result. ENCORE represents a novel approach in the provision of cardio-oncology expertise for autoBMT PTS acutely during the mobilizing and transplantation period. Future examination of our prospective dataset will elucidate the longer term effects of our interventions.
11
Mellor, Chris, David P. Reilly, and Automatic Forecasting Systems Inc. "AUTOBOX-PLUS: Version 2.0." Applied Statistics 38, no. 2 (1989): 389. http://dx.doi.org/10.2307/2348076.
Повний текст джерела
12
Amin, Chaerul, Sophia Dwiratna Nur Perwitasari, and Kharistya Amaru. "Study of dissolved oxygen quality response in smart watering and autopot systems due to the effect of changes in environmental temperature." Jurnal Agrotek Ummat 10, no. 2 (June 9, 2023): 175. http://dx.doi.org/10.31764/jau.v10i2.13347.
Повний текст джерелаАнотація:
Hydroponics is an agricultural farming system that does not use soil media but uses water media containing nutrient solutions. The purpose of this research is to measure and observe dissolved oxygen levels in the Smart Watering Unpad and Autopot Systems that have never been done before. The research was conducted using descriptive analysis method that is measuring, observing, calculating, and analysing quantitative data on hydroponic installations Smart Watering Unpad and Autopot. The fertigation used in this study were Smart Watering Unpad and Autopot with the parameters observed were ambient temperature, dissolved oxygen, and the relationship between ambient temperature and Dissolved Oxygen for 30 days of observation. The results showed that the response of dissolved oxygen levels was influenced by environmental temperature in the SWU 01 Lettuce, SWU 02, SWU 03, and SWU 01 Paprika systems had a NEGATIVE relationship direction. The Autopot system is the only installation that has a POSITIVE change in the relationship of dissolved oxygen levels influenced by ambient temperature. Autopot is a hydroponic installation that can maintain the availability of dissolved oxygen levels in the nutrient solution. The Smart Watering Unpad 02 installation can maintain the availability of dissolved oxygen levels in the nutrient solution compared to other installations in the Smart Watering Unpad system type.
13
Holowiecki, Jerzy, Sebastian Giebel, Malgorzata Krawczyk-Kulis, Jerzy Wojnar, Lucja Kachel, Maria Sadus-Wojciechowska, Beata Stella-Holowiecka, Sebastian Grosicki, and Tomasz Czerw. "Lower Relapse Incidence after Non-Cryopreserved Autologous Bone Marrow Transplantation Compared to Peripheral Blood Stem Cell Transplantation for High-Risk Hodgkin’s Lymphoma." Blood 104, no. 11 (November 16, 2004): 912. http://dx.doi.org/10.1182/blood.v104.11.912.912.
Повний текст джерелаАнотація:
Abstract In a number of studies on Hodgkin’s lymphoma (HL), autologous transplantation of peripheral blood hematopoietic stem cells (autoPBSCT) was proved to result in faster hematopoietic recovery compared to bone marrow transplantation (autoBMT), however, no difference regarding long-term outcome has been demonstrated so far. In Katowice transplant centre we developed a new method of autoBMT with bone morrow not-cryopreserved but stored for 3 days in 40C and reinfused 24 hours after completion of CBV conditioning. In this study we analyzed outcome of 40 HL patients treated with this method in comparison with 125 patients given autoPBSCT between 1993–2004. In this setting patients were treated with CBV (n=32), BEAM+/− procarbazine (n=63) or other preparative regimens (n=30). In the autoBMT group patients were transplanted in high-risk CR1 (achieved after >1 line of therapy) (25%), CR>=2 (22.5%), PR1 (35%), PR>=2 (5%), and primary or secondary refractoriness (12.5%). The indications for autoPBSCT were comparable. As well, both groups did not differ in terms of age, histological subtype, disease stage at diagnosis, organ involvement or preceding therapy. At six years, the overall- and progression-free survival for autoBMT and autoPBSCT group equaled 88% vs. 72% (p=0.1) and 69% vs. 54% (p=0.08), respectively. The relapse incidence was significantly lower for patients given autoBMT compared with autoPBSCT (23% vs. 41%, p=0.03). In a univariate analysis, among other analyzed factors (age, disease stage at diagnosis and at transplantation, organ involvement, histological subtype, conditioning regimen, preceding therapy), the only factor influencing the risk of relapse was disease status at transplantation (CR or PR vs. NR - 32% vs. 62%, p=0.001). In a multivariate analysis the impact of both disease status (p=0.001) and the source of stem cells (p=0.04) remained statistically significant. The 100 days incidence of non-relapse mortality equaled 2.5% for autoBMT and 1% for autoPBSCT (p=NS). The neutrophil >0.5 G/L recovery was faster in the autoPBSCT group compared with autoBMT (14.7 vs. 17 d., p=0.006) whereas the difference regarding platelet >50 G/L recovery was not significant (17.5 vs. 19 d., p=NS). Both procedures did not differ in terms of severe adverse events as well as the need for blood products substitution, iv antibiotic therapy, cytokine tharapy or the time of hospital stay. CONCLUSION: AutoBMT without cryopreservation results in lower relapse rate in high-risk HL patients compared with autoPBSCT. Although the neutrophil recovery is longer by 2.5 days, the toxicity of both procedures as well as the need for supportive treatment is comparable.
14
Hajdrowski, Krzysztof. "Człowiek jak automat czy automat jak człowiek?" WIADOMOŚCI ELEKTROTECHNICZNE 1, no. 6 (June 5, 2016): 5–12. http://dx.doi.org/10.15199/74.2016.6.1.
Повний текст джерела
15
Dwiratna, Sophia. "PENENTUAN KOMPOSISI MEDIA TANAM TERBAIK UNTUK BUDIDAYA SELADA MERAH MENGGUNKANA SISTEM AUTPOT MODIFIKASI." Jurnal Pertanian Tropik 4, no. 3 (December 1, 2017): 219–27. http://dx.doi.org/10.32734/jpt.v4i3.3097.
Повний текст джерелаАнотація:
Autopot an irrigation device which is operated automatically and is capable of providing nutrition in plants without the need for electrical energy. The system is operated via a smart valve that is used to open and close automatically irrigation water by the water conditions in the network system, especially the water level in the network. Basic water level is used as a mechanical sensor for opening and closing the valve automatically without the aid of another power. With these advantages, autopot able to provide water and energy efficiency is very high on a commercial scale hydroponic cultivation. It's just that the system requires very high investment and must be imported. Therefore, this study was conducted to modify the Autopot use of materials and simple equipment and test its performance on the cultivation of red lettuce. Autopot modifications performed on tools, growing media and fertigation systems are smart valve replacement valves using a hole in the bottle that works with pressure and gravity. This study aims to determine the performance test auto pot modification results in the cultivation of red lettuce as well as to determine the ratio of planting media best on auto pot system modifications. Research carried out for 90 days in a greenhouse using descriptive methods. The results showed Autopot Modifications have an average efficiency of the provision of water by 75.86% - 88.05% and an average efficiency of water use by 51.43 kg / m3-88.72 kg / m3, this efficiency is high because of high dihasikan crop production with the use of water low. Planting media between rice husk and humus in the ratio of 50:50 compositions show results better plant growth compared with other growing media composition. plants with irrigation efficiency levels are very high as well minus the electric energy consumption.
16
Rauchfuss, Julia. "Autobox and its use in Dendroecology." Tree-Ring Research 67, no. 1 (January 2011): 63–64. http://dx.doi.org/10.3959/2010-8.1.
Повний текст джерела
17
Gunjur, Ashray. "Outcomes after autoBMT in cancer survivors." Lancet Oncology 19, no. 6 (June 2018): e286. http://dx.doi.org/10.1016/s1470-2045(18)30325-5.
Повний текст джерела
18
Cassileth, P. A., J. Andersen, H. M. Lazarus, O. M. Colvin, J. M. Bennett, E. A. Stadtmauer, H. Kaizer, R. S. Weiner, M. Edelstein, and M. M. Oken. "Autologous bone marrow transplant in acute myeloid leukemia in first remission." Journal of Clinical Oncology 11, no. 2 (February 1993): 314–19. http://dx.doi.org/10.1200/jco.1993.11.2.314.
Повний текст джерелаАнотація:
PURPOSE The Eastern Cooperative Oncology Group conducted a prospective study of postremission high-dose chemotherapy and autologous bone marrow transplantation (autoBMT) in a group of uniformly treated adults with de novo acute myeloid leukemia (AML) to evaluate whether intensive, myeloablative therapy in first complete remission (CR) could improve the disease-free survival. PATIENTS AND METHODS After initial CR was induced by the combination of daunorubicin, cytarabine, and thioguanine, patients not eligible for allogeneic bone marrow transplantation (alloBMT) were offered autoBMT. Within a median of 2 months after CR, and without intervening postremission therapy, bone marrow was obtained, purged by exposure to 4-hydroperoxycyclophosphamide (4-HC), and cryopreserved. High-dose therapy consisted of oral busulfan over 4 days (16 mg/kg total) followed by intravenous (IV) cyclophosphamide 50 mg/kg daily for 4 days. The cryopreserved marrow was then reinfused. RESULTS Of the 39 patients scheduled for autoBMT, four relapsed before transplantation. Two of the 35 (6%) transplant patients died of transplant-related complications, and 11 (33%) relapsed a median of 8 months after marrow reinfusion. No relapse has occurred after 24 months posttransplant. With a median follow-up of 31 months, the median disease-free survival period for all 39 patients has not been reached; however, 54% +/- 16% of patients are projected to be alive and disease-free at 3 years. CONCLUSION Long-term, disease-free survival after autoBMT in AML seems to be better than the outcome after conventional-dose postremission therapy and rivals the results of alloBMT.
19
Samara, Yazeed, and Matthew Mei. "Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies." Cancers 14, no. 7 (March 29, 2022): 1738. http://dx.doi.org/10.3390/cancers14071738.
Повний текст джерелаАнотація:
Standard treatment for relapsed and/or refractory (r/r) Hodgkin lymphoma (HL) consists of salvage therapy, historically consisting of multiagent cytotoxic chemotherapy, followed by autologous stem cell transplantation (autoHCT) in responding patients. With this approach, most patients can proceed to autoHCT, of whom approximately half are cured. However, the introduction of the novel agents brentuximab vedotin (BV) and the checkpoint inhibitors (CPI) nivolumab and pembrolizumab has changed the decision making and peri-transplant decision making, as early incorporation of one or more of these agents can reduce or even eliminate the need for cytotoxic chemotherapy prior to autoHCT. Furthermore, post-autoHCT maintenance therapy with BV has also been shown to decrease relapse in high-risk rel/ref HL patients. In this review, we survey the current data regarding autoHCT in HL with a focus on pre-autoHCT salvage as well as maintenance strategies, and we also talk about the emerging data challenging the long-held dogma of chemosensitivity being a requirement for successful autoHCT.
20
Tholen, E., H. Brandt, H. Henne, F. J. Stork, and K. Schellander. "Genetische Fundierung von AutoFOM-Merkmalen." Archives Animal Breeding 44, no. 2 (October 10, 2001): 167–80. http://dx.doi.org/10.5194/aab-44-167-2001.
Повний текст джерелаАнотація:
Abstract. Title of the paper: Genetic foundation of AutoFOM-traits Since the beginning of the year 2000 the payment System of pig carcasses in some slaughter houses in northwest Germany is based on the recordings of the fully automated carcass Classification system AutoFOM. Besides legal information 'estimated lean meat percentage' relative exact details of the weights of important valuable cuts are available. Genetic parameters of the AutoFOM lean carcass cut information, ham-, chop-, Shoulder- and belly weights as well as lean meat percentage of the belly cut were estimated. Using the field data of the pig breeding organisations BHZP (n = 2224) and SNW (n = 3601) the estimated heritabilties of these carcass cuts vary between 0.13 and 0.27 (BHZP) and 0.13 and 0.31 (SNW), respectively. The estimated heritabilities of the AutoFOM carcass traits of station-tested pigs were more pronounced for the dam lines German Landrace and Large White (n = 1693) and Piétrain Al-boars mated to Fl sows (n = 1053). The estimates ranged from 0.27 to 0.59 (dam lines) and 0.05 to 0.40 (Pi Al-boars), respectively. Using the records of Station tested purebred Pietrain pigs (n = 1693) the heritabilities of the AutoFOM carcass cuts did not exceed 0.10. The genetic correlation between the different AutoFOM carcass traits exceed the absolute value of 0.8. In a similar way, the genetic correlation between the "estimated lean meat percentage" used in the test Station and the AutoFOM carcass traits were close to unity. We concluded that AutoFOM traits of slaughter pigs provide a useful information for the selection of Al-boars. Moreover, with regard to the Station testing of dam lines AutoFOM carcass informations derived from AutoFOM are a useful supplementation. Because of the low heritability, only a marginal additional benefit could be expected for the genetic ranking of Pi-boars using AutoFOM carcass cut records of purebred Station tested progenies.
21
Fuster, Francisco. "Viaje en autobús." Hispanic Research Journal 22, no. 2-3 (May 4, 2021): 250–53. http://dx.doi.org/10.1080/14682737.2021.2030573.
Повний текст джерела
22
Scott, J. "IN THE AUTOMAT." Common Knowledge 10, no. 3 (October 1, 2004): 551–64. http://dx.doi.org/10.1215/0961754x-10-3-551.
Повний текст джерела
23
Wahyuningsih, Erfiana, Sulistyo Widodo, and Randy Rahmanto. "PEMBUATAN PROTOTYPE ROBOT COVID-19 ARJUNO AUTOBOST." Jurnal Teknika dan Informatika (JTI) 1, no. 1 (May 16, 2021): 25–33. http://dx.doi.org/10.52909/jti.v1i1.8.
Повний текст джерелаАнотація:
Robot arjuno autobost merupakan robot pendeteksi suhu yang dirancang dengan alat-alat ramah lingkungan, dan dibuat dengan sebaik mungkin. Sistem robot ini bisa menghampiri orang atau benda yang di depannya dan akan mendeteksi suhu dengan mengelauarkan suara untuk perintahnya.Robot arjuno ini juga merupakan salah satu alat teknologi untuk membantu manusia dalam bekerja terutama mengecek suhu dan memberikan hansanitizer. Kami menciptakan robot ini agar untuk membantu pekerjaan manusia, tanpa mengganti pekerjaan manusia karna robot yang kami buat juga harus ada maintenen nya, hanya saja awalnya yang bekerja harus banyak orang, kemudian adanya robot arjuno ini satu orang juga cukup. Dari hasil analisis dan pembuatan robot ini diharapkan memproleh hal-hal yang menjadi perhatian untuk dilakukan langkah-langkah dalam pelaksanaan pengendalian dari system Arjuno ini dengan demikian performacenya dapat dijaga sesuai dengan kondisi awal dan dijadikan rekomendasi untuk para pemangku kepentingan.
24
Maliske, Seth M., Matthew J. Maurer, Carrie A. Thompson, Luis Porrata, Ivana Micallef, Rebecca L. King, Sergei Syrbu, et al. "Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 2896. http://dx.doi.org/10.1182/blood-2019-124579.
Повний текст джерелаАнотація:
Introduction: Front-line immunochemotherapy (IC) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is expected to cure 60-70% of newly diagnosed DLBCL. Up to one third of newly diagnosed DLBCL patients will have relapsed or refractory (r/r) disease.1 Current standard of care for these patients is salvage chemotherapy and, if chemosensitive, to be followed by high dose chemotherapy with hematopoietic cell rescue (autoHCT).2,3 Event-free survival at 24 months (EFS24) after frontline IC is associated with excellent long-term outcomes with overall survival (OS) similar to that of age- and sex-matched controls.4 In comparison, those achieving EFS24 following autoHCT for relapsed or refractory disease may have increased risk for late-mortality compared to the general population with advanced age and intensive salvage therapy contributing to the risk of late complications.5 We sought to better characterize EFS24 after autoHCT to determine the utility of this end-point for informed clinical decisions, patient management, and future clinical trials. Methods: Patients were prospectively enrolled onto the Molecular Epidemiology Resource (MER) of the University of Iowa/ Mayo Clinic Specialized Program of Research Excellence (SPORE). Patients were followed for relapse, retreatment, and death; all events were validated by medical record review. For this analysis patients were included if they were consented within 9 months of initial diagnosis of DLBCL between 2002-2012, had received anthracycline-based IC (R-CHOP, or similar), and eventually had undergone autoHCT for r/r DLBCL. Patients with primary central nervous system (CNS) lymphoma or post-transplant lymphoproliferative disorders (PTLD) were excluded. Overall survival (OS) was defined as time from autoHCT until death due to any cause. Event-free survival (EFS) was defined as time from autoHCT until progression, relapse, retreatment, or death due to any cause. OS from achieving EFS24 after autoHCT was compared to age- and sex-matched general US population. Results: 108 patients underwent autoHCT for relapsed DLBCL between 2002 and 2017. Median age at autoHCT of the patients was 60 years (range 20-78) and 72 (67%) were male. The most common transplant conditioning regimen was BEAM (82%). At a median follow-up after autoHCT of 85 months (range 1-171), 72 patients (67%) had an event and 64 patients (59%) had died. Kaplan-Meier estimates for EFS and OS at 24 months from the time of autoHCT were 49% (95% CI: 40-59) and 61% (95% CI: 52-71), respectively. 52 patients had a progression within 24 months of autoHCT; OS from progression was poor (median OS=2.8 months, 95% CI: 1.8-6.0; 5 year OS = 9%, 95% CI: 2-22). 48 patients achieved EFS24 after autoHCT; median OS from achieving EFS24 was 136 months (95% CI: 92-NE) and 5 year OS was 79% (95% CI: 68-93). This was inferior to the background population (Figure 1, SMR=3.64, 95% CI: 2.11-6.27, p<0.0001). Eight patients had a progression after achieving EFS24 from autoHCT. OS from progression in these 8 patients (median OS=27.3 months, 95% CI: 14.4-NE; 5 year OS = 16%, 95% CI: 3-93) was improved compared to progression within 24 months of autoHCT (p=0.072, figure B). Cause of death (COD) in EFS24 achievers was progression of lymphoma (n=6), infection (n=1), secondary malignancy related to therapy (n=3), heart disease (n=1), and unknown (n=1). Conclusions: Patients achieving EFS24 after salvage chemotherapy and autoHCT have a favorable long-term prognosis; however, overall survival remained inferior to the general population. Most common COD after achieving EFS24 was progression of lymphoma. In spite of this, EFS24 remains a valuable end-point for informed clinical decisions, patient management, and future clinical trials. Figure 1 Disclosures Maurer: Morphosys: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; Nanostring: Research Funding. Ansell:Mayo Clinic Rochester: Employment; Bristol-Myers Squibb: Research Funding; Affimed: Research Funding; Trillium: Research Funding; Regeneron: Research Funding; Seattle Genetics: Research Funding; Mayo Clinic Rochester: Employment; Affimed: Research Funding; Bristol-Myers Squibb: Research Funding; LAM Therapeutics: Research Funding; Regeneron: Research Funding; Seattle Genetics: Research Funding; Trillium: Research Funding; LAM Therapeutics: Research Funding. Cerhan:Celgene: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; NanoString: Research Funding. Farooq:Celgene: Honoraria; Kite Pharma: Research Funding.
25
Smith, Sonali, Linda J. Burns, Koen van Besien, Jennifer LeRademacher, Wensheng He, Ginna G. Laport, Silvia Montoto, David G. Maloney, and Parameswaran Hari. "Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis." Blood 116, no. 21 (November 19, 2010): 689. http://dx.doi.org/10.1182/blood.v116.21.689.689.
Повний текст джерелаАнотація:
Abstract Abstract 689 T-cell lymphomas (T-NHL) are aggressive, heterogeneous malignancies, marked by chemoresistance with fewer than one-third of patients achieving disease control with non-transplant therapies. There are no large comparative studies of autoHCT and alloHCT in T-NHL. We analyzed post-transplant outcomes of 241 recipients (≤ 60 yrs) of autoHCT (n=115) and alloHCT (n=126, 76 matched siblings) for T-NHL between 1996–2006 reported to the CIBMTR. Median age was 43 yrs for autoHCT and 38 yrs for alloHCT. In the alloHCT cohort: 59% received myeloablative conditioning, 60% had matched sibling donors. Histology was heterogeneous (Table 1). Median time to transplant after diagnosis was similar in both groups (10m vs. 11m). AutoHCT, compared to alloHCT, was used more in ALCL (53% vs. 40%, p=0.04) and in those with less advanced and more sensitive disease: first complete remission (CR1) (35% vs. 14%, p=0.001), chemosensitive disease (86% vs. 60%, p<0.0001), and ≤ 2 lines prior therapy (65% vs. 44%, p<0.001). Median follow-up was 71m for autoHCT and 49m for alloHCT. Treatment related mortality (TRM) at 100 days in the autoHCT and alloHCT cohorts was 2% and 17%, respectively. For those beyond CR1, overall survival (OS) at 1 yr was 62% vs. 52% and at 3-yrs 53% vs. 41% for the autoHCT and alloHCT cohorts, respectively (Table 2). Relapsing T-NHL was the cause of death in 73% of autoHCT and 44% of alloHCT pts. In multivariate analysis, alloHCT and more pretransplant chemotherapy regimens were associated with a higher risk of TRM. Relapse risk was higher with chemotherapy resistant disease and those not in CR. PFS and OS were similar after autoHCT or alloHCT with a greater number of prior chemotherapy regimens and chemotherapy resistance impacting survival outcomes adversely. Among 101 peripheral T cell lymphoma (PTCL) pts, the risk of relapse was significantly lower with alloHCT (RR 0.5, 95% CI 0.26–0.97) but countered by increased TRM for alloHCT (RR 3.03, 95% CI 1.02 –8.96). PFS and OS after autoHCT or alloHCT for PTCL were similar and adversely affected by pretransplant chemotherapy resistance. Among alloHCT recipients, there were no differences in outcomes based on donor source, conditioning regimen type or intensity. In summary, pts undergoing autoHCT for T cell NHL appear to be selected for less advanced disease and greater chemosensitivity, making direct outcome comparisons with alloHCT difficult. AlloHCT is an effective strategy for high risk patients, albeit with significant TRM. Higher numbers of chemotherapy regimens prior to transplant adversely impacted both TRM and survival, suggesting that HCT should be considered earlier in the disease course. Disclosures: No relevant conflicts of interest to declare.
26
Hayes-Lattin, Brandon, Jeanette Carreras, Mei-Jie Zhang, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, J. Douglas Rizzo, and Parameswaran Hari. "Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity." Blood 108, no. 11 (November 16, 2006): 3021. http://dx.doi.org/10.1182/blood.v108.11.3021.3021.
Повний текст джерелаАнотація:
Abstract No randomized trials have compared autologous HCT (autoHCT) to allogeneic HCT (alloHCT) for DLBCL. We analyzed the outcomes of 916 patients (pts) (837 autoHCT and 79 alloHCT) ages 18–60yrs after a first autoHCT or HLA-identical sibling alloHCT for DLBCL between 1995 and 2003 reported to the CIBMTR. Pts receiving T-cell depleted allografts or reduced-intensity conditioning were excluded. There were significant baseline differences between the groups in disease stage, B symptoms, extranodal disease and marrow involvement. AlloHCT pts were significantly more likely to have >3 chemo regimens prior to HCT (53 vs 40%), and resistant induction failure or relapse (39 vs 16%). At 1yr, treatment-related mortality (TRM) was higher after alloHCT (41%, 95% CI, 30–52%) than after autoHCT (11%, 95% CI, 9–14%, p<0.001), but risks of relapse/progression were similar (30%, 95% CI, 21–41%) and (33%, 95% CI, 29–36%, p=0.69), respectively. Cumulative incidence of outcomes and univariate probabilities of progression free (PFS) and overall survival (OS) at 5 yrs are summarized in table 1. In multivariate analysis, allo and autoHCT had differential early and late effects on outcomes. In the first 12 mo after transplant, alloHCT was associated with higher TRM (RR 4.76, 95% CI, 3.14–7.22, p<0.001), treatment failure (RR 2.08, 95% CI, 1.56–2.77, p<0.001) and mortality (RR 2.78, 95% CI, 2.06–3.77, p<0.001) but similar risk of progression (RR 1.14, 95% CI, 0.75–1.74, p=0.54) compared to autoHCT. Among pts surviving 12 mo post-transplant, no significant difference was observed between autoHCT and alloHCT for TRM, progression, PFS, or OS. Covariates that increased the risks of TRM and OS were older age (51–60 years), KPS <90%, chemoresistance at transplant, and earlier transplant yr (before 2001 vs later). Older age and chemoresistance were also associated with progression and lower PFS. There were no significant interactions between graft type and other prognostic variables; in particular, relative risk of outcomes with allo vs autoHCT were similar for patients with chemosensitive and chemoresistant disease. In summary, myeloablative alloHCT increased risks of early TRM and mortaliy without an effect on progression (compared to autoHCT). Transplant type did not affect outcomes after 12 months post-transplant. AutoHCT was associated with superior survival (fig 1), and the difference was not explained by differences in chemosensitivity at the time of transplant. AutoHCT AlloHCT Outcomes (95%CI) (95%CI) AGVHD @ day 100 N/A 42 (31–53) CGVHD @ 5yrs N/A 27 (18–38) TRM @ 5yrs 18 (15–20) 45 (34–57) Relapse/progression @ 5yrs 39 (36–43) 33 (23–44) PFS @ 5yrs 43 (40–46) 26 (18–37) OS @ 5yrs 49 (46–53) 27 (18–27) Figure 1 Figure 1.
27
S Indurkar, Maya, Manjiree S Awad, Astrid Lobo Gajiwala, Urmila Samant, and Cynthia D'Lima. "AutoBT: A new Paradigm in Periodontal regeneration." Journal of International Medicine and Dentistry 5, no. 2 (September 25, 2018): 51–55. http://dx.doi.org/10.18320/jimd/201805.0251.
Повний текст джерела
28
Sánchez-Ortega, Isabel, Grzegorz W. Basak, Eric Beohou, Steffie van der Werf, Myriam Labopin, Anja van Biezen, Nicolaus Kroeger, et al. "Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT." Blood 128, no. 22 (December 2, 2016): 678. http://dx.doi.org/10.1182/blood.v128.22.678.678.
Повний текст джерелаАнотація:
Abstract INTRODUCTION: Age is no longer a barrier to successful autologous hematopoietic cell transplantation (autoHCT). Improved stem cell mobilization and supportive care are potentially making autoHCT more feasible in elderly patients in recent years. However, reports of autoHCT outcomes in elderly patients aged 65 years-old (yo) and older are limited. These patients are underrepresented in clinical trials and data usually come from relatively small series and subgroup analyses in the main indications, namely multiple myeloma (MM) and lymphoproliferative disorders (LPD). Here, we sought to evaluate the feasibility and general outcomes of the autoHCT procedure in a large cohort of elderly patients reported to the EBMT. PATIENTS AND METHODS: All consecutive autoHCT in recipients 65 yo and older reported to the EBMT between 2000 and 2014 were included. Data collection and outcome analysis followed EBMT registry and statistical guidelines. RESULTS: A total of 21390 autoHCT, including 3514 second or subsequent procedures, from 515 EBMT centres in 45 countries were identified: the median age was 67 (65-89), 17531 were 65-69 yo (Group I) and 3859 were 70 yo and older (Group II); 61% were male; 62% had MM, 30.5% LPD, 3.4% acute leukemia and 3.3% other indications; 99% of cases in both age groups used peripheral blood stem cells, and 10.3% of cases received reduced-dose preparative regimens for advanced age. Median time from diagnosis to autoHCT was 8.9 months (IQR 5.9-18.7), significantly longer for group II (9.4 vs 8.8 months; p <0.001). AutoHCT activity in elderly patients increased over the study period from 443 out of 13163 in 2000 (3.4%) to 2444 out of 23883 in 2014 (9.8%; p<0.001). Neutrophil and platelet engraftment were achieved after a median day +12 (IQR 10-13) and +17 (IQR 14-22), respectively, and 1.4% of the cases experienced primary or secondary graft failure. The main early complication after autoHCT was mucositis (67.5%). Venooclusive disease was diagnosed in 0.8% of cases. The incidence of transplant complications did not differ between age groups. Median follow up time for survivors was 15.3 months (IQR 4.2-41.7), significantly longer for group I than for group II (15.9 vs 13.3; p<0.001). Non-relapse mortality (NRM) was 4.9% [95%CI 4.6-5.2] at 1 year and 8.3% [95%CI 7.8-8.7] at 3 years, significantly higher for Group II both at 1 year (4.6% [95%CI 4.3-5] vs 5.9% [95%CI 5.1-6.8]) and 3 years (7.8% [95%CI 7.4-8.3] vs 10.4% [95%CI 9.2-11.6], p<0.001) after autoHCT (Figure 1). Relapse incidence was 21.6% [95%CI 21-22] at 1 year and 50% [95%CI 50-51.8] at 3 years, significantly higher for group II both at 1 year (20.6% [95%CI 19.9-21.3] vs 26.6% [95%CI 25-28.2]) and 3 years (50% [95%CI 49-51] vs 55% [95%CI 53-57], p<0.001) after autoHCT. Causes of death included relapse or disease progression (76%), transplant related mortality (9.4%), secondary malignancies (4.2%) and others (10.3%). Overall survival (OS) was 87% [95%CI 86.5-87.5] at 1year and 66.7% [95%CI 66.8-68.5] at 3 years, significantly lower for Group II both at 1 year (87.7% [95%CI 87.2-88.3] vs 83.4% [95%CI 82-84.7]) and 3 years (69.1% [95%CI 68.2-70] vs 60.8% [95%CI 58.8-62.9], p<0.001) after autoHCT. Multivariate analysis showed that increased age (in 5-year intervals), diagnoses other than MM, and time from diagnosis to autoHCT >12 months all had an independent negative impact on NRM and OS (Table 1). In addition, more recent year of transplantation had an additional independent favorable impact on OS. CONCLUSIONS: Our results confirm the feasibility of autoHCT in a large-series of elderly patients, with acceptable NRM and OS at 1 and 3 years overall, despite the significant poorer outcomes in those 70 yo and older. In addition, this study identifies in multivariate analysis factors that have an independent impact on NRM and OS of elderly patients undergoing autoHCT. With the limitations of a retrospective registry analysis, this is presumably a highly selected fraction of patients aged 65 and older considered for autoHCT. Nevertheless, our data in a large cohort of such patients convincingly suggest that age per se should not be an exclusion criteria to consider autoHCT in this population. Thus, they also further endorse the need to assess comorbidity and frailty beyond age in older autoHCT candidates to improve outcomes further. Studies to assess the benefit from autoHCT in elderly patients with particular diseases and indications are warranted. Disclosures Montoto: Roche: Honoraria; Gilead: Research Funding. Dreger:Novartis: Consultancy; Gilead: Consultancy; Janssen: Consultancy; Gilead: Speakers Bureau; Novartis: Speakers Bureau; Roche: Consultancy. Goldschmidt:Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Chugai: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Onyx: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Garderet:BMS: Consultancy, Honoraria; Amgen: Consultancy; Takeda: Consultancy; Novartis: Consultancy.
29
Godfrey, James K., Sonali M. Smith, Kwang Woo Ahn, Alyssa Digilio, Timothy S. Fenske, Anna M. Sureda, and Mehdi Hamadani. "Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 7508. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7508.
Повний текст джерелаАнотація:
7508 Background: Contrary to most FL, high-risk FL pts with ECF (i.e. relapse within 2 yrs of frontline chemoimmunotherapy) have a 5 yr OS of only 50%. (Casulo, JCO 2015). We used the CIBMTR database to compare autoHCT versus either MSD or MUD alloHCT as the first transplant approach in FL pts with ECF. Methods: Adult FL pts (age ≥18) undergoing autoHCT or alloHCT between 2002-2014 and receiving first line rituximab-based chemoimmunotherapies with evidence of ECF (defined as disease relapse or progression within 2 yrs of treatment initiation) were included. The primary endpoint was OS; secondary endpoints were progression-free survival (PFS), relapse and non-relapse mortality (NRM). Results: 440 pts had ECF (auto = 240, MSD = 105, MUD = 95) (Table 1). The 5 yr adjusted probabilities (AjP) of NRM were significantly lower with autoHCT (5%), versus MSD (17%) or MUD (33%) HCT (p<0.0001). 5 yr AjP of relapse were significantly lower with MSD (31%) or MUD HCT (23%), versus autoHCT (58%; p<0.0001). AjP of 5 yr PFS following auto, MSD and MUD HCT were 38%, 52% and 43% (p=.006) respectively. The AjP of 5 yr OS was significantly higher following autoHCT (70%) or MSD HCT (73%) versus MUD HCT (49%; p=0.004). Conclusions: AutoHCT for FL pts with ECF has low NRM and 5 yr OS rates (70%) that are provocatively higher than historical data (~50%). MSD HCT had the lowest relapse rate with similar survival. A prospective trial confirming the role of HCT in ECF FL is warranted. [Table: see text]
30
Sadaoui, N., J. Janin, and A. Lewit-Bentley. "The Orsay crystallization automat." Acta Crystallographica Section A Foundations of Crystallography 49, s1 (August 21, 1993): c389. http://dx.doi.org/10.1107/s0108767378089072.
Повний текст джерела
31
Gajewski, James L., Jeanette Carreras, Hillard M. Lazarus, Ginna G. Laport, Silvia Montoto, David G. Maloney, and Parameswaran Hari. "The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)." Blood 116, no. 21 (November 19, 2010): 2390. http://dx.doi.org/10.1182/blood.v116.21.2390.2390.
Повний текст джерелаАнотація:
Abstract Abstract 2390 Burkitt lymphoma (BL) is an aggressive B cell lymphoma primarily affecting children and young adults and is characterized by the highest doubling time of any tumor. Cyclical intensive chemotherapy and rituximab confer high complete remission (CR) rates and 80% long term disease free survival in chemotherapy sensitive disease. The role of autologous (autoHCT) or allogeneic (alloHCT) transplant is not well described in BL. We report the outcomes of 241 recipients of HCT for BL between 1985 and 2007 reported to the CIBMTR. Five patients (pts) received syngeneic twin grafts in addition to autoHCT in 113 pts, HLA identical sibling alloHCT (SIB) in 80 pts and mismatched related or unrelated donor (UNR/MM) alloHCT in 48 pts. Baseline patient and disease related risk factors varied significantly between cohorts (table1). The autoHCT cohort had a higher proportion of pts with chemotherapy sensitive disease (86%), peripheral blood grafts (73%) and HCT in first CR (42%). In the UNR/MM cohort, 25% pts were chemotherapy resistant and only 6% were in CR1. The use of autoHCT has declined in recent years with the majority (81%) performed before 2001. Conditioning regimen for alloHCT was myeloablative in 88% (86% and 92% in SIB and UNR/MM respectively). Treatment related mortality (TRM) was higher in alloHCT recipients (table1). Cumulative incidence of relapse/progression at 5 yrs (95% CI) was 44 (35-53)% for autoHCT, 42(31-53)% for SIB and 48 (34-62)% for UNR/MM. For autoHCT, 5-yr progression free survival (PFS) was 48(39-58)%, 78% for those in first CR versus 27% for disease beyond CR1 (p<0.001). For alloHCT, 5-yr PFS was 50% for those in first CR versus 19% for disease beyond CR1 (p=0.001) (figure 1). 5-yr PFS was 30 (20-41)% for SIB and 22 (12-35)% for UNR/MM. Progressive BL was the commonest cause of death. Conclusion: While autoHCT and alloHCT are both feasible in patients with BL, the use of autoHCT appears to be declining in recent years concomitant with the advent of modern chemotherapy. AlloHCT was performed in those with considerably higher risk disease. Approximately one fifth of advanced BL pts receiving alloHCT beyond CR1 had long term disease free survival. Disclosures: No relevant conflicts of interest to declare.
32
Fürst, Yannick, Andrea Ruiz, Dennis Herrmann, Stefan Brandt, and Martin Kriegel. "Thermohydraulische Optimierung nach dem Add-on-Prinzip." HLH 73, no. 09 (2022): 34–37. http://dx.doi.org/10.37544/1436-5103-2022-09-34.
Повний текст джерелаАнотація:
Zunehmende energetische Anforderungen bei der Betriebsführung von Wärmeverteilsystemen erfordern im Kontext der Wärmewende geringinvestive Ansätze zur Anlagenoptimierung. Im Forschungsvorhaben „AutoBop“ werden daher Betriebsoptimierungsverfahren untersucht und entwickelt, die nach dem Add-on-Prinzip in bestehende Heizungssysteme integriert werden können und binnen kürzester Zeit für einen effizienteren Betrieb sorgen.
33
Virk, Ramandeep S. "The Autobots are Here to Stay: Robotics in Medicine." Journal of Postgraduate Medicine, Education and Research 49, no. 2 (2015): 0. http://dx.doi.org/10.5005/jpmer-49-2-iv.
Повний текст джерела
34
Klocke, J., M. Cannon, C. Devoe, D. Gissinger, V. John, and R. L. Bayer. "Prevention of mucositis in AutoBMT/stem cell transplant patients." Biology of Blood and Marrow Transplantation 12, no. 2 (February 2006): 100–101. http://dx.doi.org/10.1016/j.bbmt.2005.11.310.
Повний текст джерела
35
Kim, Yundeok, Jung Yeon Lee, Hyun Sung Park, Ji Eun Jang, Soo-Jeong Kim, Jin Seok Kim, June-Won Cheong, and Yoo Hong Min. "Salvage Chemotherapy Followed By Autologous Peripheral Stem Cell Transplantation for Relapsed Acute Promyelocytic Leukemia; A Single Center Experience." Blood 124, no. 21 (December 6, 2014): 4000. http://dx.doi.org/10.1182/blood.v124.21.4000.4000.
Повний текст джерелаАнотація:
Abstract Background: After the addition of differentiating agents such as all-transretinoic acid (ATRA) to conventional chemotherapy, treatment outcomes of acute promyelocytic leukemia (APL) had been markedly improved. However, about 10% of patients with APL still have experienced relapse and have to receive salvage chemotherapy. Although arsenic trioxide (ATO) plays an important role in salvage chemotherapy as well as induction chemotherapy, the optimal treatment strategy remains unclear, especially for patients in whom autologous peripheral stem cell transplantation (AutoHCT) is planned. We tried to find the role of salvage chemotherapy including ATO-based regimen in relapsed APL patients, and want to share our experience in these patients. Patients and Methods: Among 77 patients diagnosed with APL from 2005 to 2014 at Yonsei University Severance Hospital, 11 (14.3 %) relapsed patients were enrolled. Clinical data of these patients was retrospectively reviewed. Except one patient refused further treatment at the time of relapse, 10 patients were included in the final analysis for treatment outcome. Results: All patients received remission induction chemotherapy with modified PETHEMA regimen, and achieved complete remission (CR) confirmed at the molecular level. The median duration of the first CR was 38.8 months (range 28.0–88.0 months). As pre-transplant salvage chemotherapy, earlier 3 patients received conventional chemotherapy regimen without ATO, but later 7 patients received ATO-based regimen after ATO was available in our country. There was no statistical difference in median duration to the second CR from salvage chemotherapy according to the regimen (68 days in conventional chemotherapy patients vs. 60 days in ATO-based chemotherapy, P>0.05). However, 3 patients receiving conventional regimen without ATO did not received AutoHCT because they died due to treatment-related complications during additional salvage chemotherapies. In contrast, 7 patients receiving ATO-based regimen received AutoHCT successfully, and all patients remains alive without further relapse. The median duration from the time of second CR to AutoHCT was 3.8 months (range 1.3–7.6 months), and median follow up duration after AutoHCT was 8.3 months (range 0.6–45.9 months). In these 7 patients receiving ATO-based regimens, duration of ATO treatment was variable (median 72 days, range 42-113 days), and a range of total dose of ATO given before AutoHCT was also variable (median 701.23 mg, range 420-1242.8 mg). Total dose and treatment duration of ATO was mainly determined by the time of molecular CR achieved again. The peripheral hematopoietic stem cells were harvested when molecular complete remission was confirmed, and median number of stem cells harvested was 5.14 x 10^6 cells/kg of recipient (range 2.90–7.76 x 10^6 cells/kg). The yield of harvest peripheral stem cells and the outcomes of followed AutoHCT were not significantly related to the total dose or treatment duration of pre-transplant ATO-based salvage therapy. Conclusion: In this study, ATO-based chemotherapy followed by AutoHCT was safe and excellent salvage treatment strategy for relapsed APL patients. The achievement of second molecular CR might be more important in this treatment strategy than total dose or treatment duration of ATO-based salvage therapy before AutoHCT. Disclosures No relevant conflicts of interest to declare.
36
Rios de Rodriguez, Carroll. "10 ateos cambian de autobús." Revista Fe y Libertad 1, no. 2 (December 31, 2018): 4. http://dx.doi.org/10.55614/27093824.v1i2.27.
Повний текст джерелаАнотація:
A este corto tomo, 10 ateos cambian de autobús, imprime el ritmo acelerado de nuestra era. No se anda con rodeos. No empieza por contarnos cuándo nacieron y qué estudiaron los famosos intelectuales reseñados en las páginas: da por hecho que los lectores ya conocemos a sus protagonistas. No compara. No los ordena cronológicamente. No balancea, de forma políticamente correcta, las nacionalidades, las profesiones, la etnia o el sexo (únicamente dos capítulos se dedican a mujeres). Los capítulos difieren.
37
Scott, Colin E. "Aluminium sheet for autobody construction." Matériaux & Techniques 83, no. 10-11 (1995): 21–27. http://dx.doi.org/10.1051/mattech/199583100021.
Повний текст джерела
38
Guanche Garcell, Humberto, Carlos Martínez Quesada, Carlos E. García Ternblom, Francisco Gutiérrez García, and Rosa Peña Sandoval. "Alcoholismo en conductores de autobús." Gaceta Sanitaria 20, no. 6 (November 2006): 513. http://dx.doi.org/10.1157/13096507.
Повний текст джерела
39
Watts, Justin M., Lynette Zickl, Mark R. Litzow, Selina M. Luger, Hillard M. Lazarus, Peter A. Cassileth, Hugo F. Fernandez, et al. "Practically All Patients with Acute Myeloid Leukemia (AML) in Continuous Complete Remission for 3 Years or More Are Cured of Their Disease: The ECOG Experience." Blood 120, no. 21 (November 16, 2012): 132. http://dx.doi.org/10.1182/blood.v120.21.132.132.
Повний текст джерелаАнотація:
Abstract Abstract 132 Late relapse in acute myeloid leukemia (AML) has been infrequently studied and variably defined in the literature. Two series have shown that late relapse of AML ≥5 years after first complete remission (CR1) is uncommon, with rates of 1.19–3% (Medeiros et al, Leuk Lymphoma 2007; Verma et al, Leuk Lymphoma 2010). We searched the long-term data available on 784 adults (<60 years-old) who were treated on 1 of 4 ECOG clinical trials (E3483, PC486, E3489, or E1900) and achieved CR1 for reports of late relapse (defined as recurrence of AML ≥3 years after CR1). Median follow-up for the 553 patients last known alive was 11.1 years. The longest median follow-up was 17.2 years on trial PC486. Outcomes We found that 11 patients (1.4%) relapsed late; of these, 2 were treated on E3483, 1 on PC486, 5 on E3489, and 3 on E1900. Seven patients with late relapse died from their disease and 4 were living at last known follow-up. Only 1 patient (0.13%) had recurrence of AML ≥5 years after achieving CR1. It is possible that more late relapses will occur on E1900 (a more recent study with ongoing follow-up). All of these trials except E3483 treated some patients with autologous hematopoietic cell transplantation (autoHCT) as part of post remission therapy. On PC486, no post remission consolidation chemotherapy was administered before autoHCT. Ninety-eight total patients on E3489 and PC486 received autoHCT, and there were no late relapses; on E1900, 2 of the 141 patients treated with autoHCT developed late relapse. No patients who underwent allogeneic (allo) HCT in CR1 experienced late relapse on any of the 4 clinical trials. Nine of the 11 patients with late relapse did not undergo HCT; of these, 5 were consolidated with high-dose cytarabine, 2 received maintenance with low-dose cytarabine and 6-thioguanine, and 2 received unknown post remission therapy. Of the 3 patients with late relapse on E1900, 2 received standard-dose and 1 high-dose daunorubicin with induction. Conclusions Across all 4 trials, only 2 of the 239 patients (0.8%) treated with post remission autoHCT experienced late relapse of AML (≥3 years after CR1), which reinforces previously published data that late relapse after autoHCT is uncommon (Cassileth et al, J Clin Oncol 1993). Furthermore, of the 35 patients treated with autoHCT on PC486, 11 relapsed early and no patients relapsed late, suggesting that post remission chemotherapy may not be necessary before autoHCT. Based on this large AML cohort of nearly 800 patients with long-term follow-up, patients who remain in CCR for at least 3 years have a very low risk of relapse and can be considered cured of their disease. Moreover, given that recurrent AML was extremely rare after 5 years or more of CCR (<0.2%), the risk of therapy-related AML from contemporary induction and post remission strategies including HCT appears to be minimal. Disclosures: No relevant conflicts of interest to declare.
40
Shah, Nirav Niranjan, Kwang Woo Ahn, Carlos Litovich, Timothy Fenske, and Mehdi Hamadani. "Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era?" Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 8000. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8000.
Повний текст джерелаАнотація:
8000 Background: In relapsed, chemosensitive DLBCL patients (pts), autoHCT consolidation is a standard therapy option. With the approval of anti-CD19 CAR T-cells in 2017, relapsed DLBCL pts with residual PET/CT avid disease after salvage therapies are increasingly being offered CAR T-cells in lieu of autoHCT. According to Center for International Blood and Marrow Transplant Research (CIBMTR) data in 2018, the number of autoHCT for DLBCL in the U.S. decreased by ~45% from prior years, likely due to application of CAR T-cells for both chemorefractory DLBCL and chemosensitive DLBCL pts not achieving a complete remission. Using the CIBMTR database, we report outcomes of autoHCT in relapsed chemosensitive DLBCL pts achieving only a PET/CT+ PR prior to HCT. Methods: 249 relapsed DLBCL pts undergoing an autoHCT from 2003-13 with a PET/CT+ PR prior to transplant were identified. The study cohort was divided into two groups: (a) early chemo-immunotherapy failure (ECF) defined as pts with primary refractory disease (PRefD) or relapse within 12 months of diagnosis, (b) late chemoimmunotherapy failure (LCF) defined as pts relapsing ≥12 months. Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS) and relapse. Results: 182 pts had ECF and 67 pts had LCF. The median age of ECF pts was 57 years versus (vs) 63 years for LCF (p < 0.01). ECF pts more frequently had stage III-IV at diagnosis (74% vs 54%, p = < 0.01). 79% of ECF pts had PRefD. The most common conditioning regimen was BEAM in both cohorts. The adjusted 5-year probabilities for PFS and OS (ECF vs LCF) was not different between the 2 cohorts: 41% vs 41% (p = 0.93) and 51% vs 63% (p = 0.09), respectively. Cumulative incidence of relapse at 5 years in similar order was 48% vs 57%, p = 0.27. On multivariate analysis compared to the LCF, pts with ECF had an increased risk of death (HR = 1.61, 95%CI 1.05-2.46, p = 0.03) but no increased risk in PFS or relapse. Conclusions: Using the CIBMTR registry, we report outcomes of relapsed DLBCL pts in a PR with residual PET/CT avid disease at time of autoHCT. While OS favored LCF pts, the adjusted 5-year PFS (41%) was comparable in both cohorts. This 5 year PFS is comparable to results reported in historical trials of auto-HCT for DLBCL. With no randomized data demonstrating superiority of CAR T-cell therapy in chemosensitive PR patients, these findings strongly support that autoHCT should remain the current standard of care for this patient population.
41
Hauser, Robert. "FIZ AutoDoc – the customer-oriented document delivery service." Interlending & Document Supply 43, no. 3 (August 17, 2015): 122–30. http://dx.doi.org/10.1108/ilds-06-2015-0019.
Повний текст джерелаАнотація:
Purpose – To describe both the service and recent developments of FIZ AutoDoc. Design/methodology/approach – An in depth description with particular emphasis on copyright issues. Findings – That FIZ AutoDoc has developed to respond to the information needs of its customers primarily in the commercial sector internationally. Originality/value – A full description of a valuable service that draws upon the resources of many partners to provide commercial organizations with the information that they need.
42
Popplewell, Leslie L., Karen Chang, Joycelynn Palmer, and Stephen J. Forman. "Large Granular Lymphocytosis Following Transplantation: Institutional Experience over a 10-Year Period at City of Hope." Blood 106, no. 11 (November 16, 2005): 2024. http://dx.doi.org/10.1182/blood.v106.11.2024.2024.
Повний текст джерелаАнотація:
Abstract Large Granular lymphocyte (LGL) expansion and LGL leukemia have been described in patients following both ablative and non-myeloablative conditioning regimens for hematopoietic cell transplantation (HCT), and have been associated with viral infection and graft-vs.-host disease (GVHD). We describe here an analysis of 41 cases of clonal LGL expansion identified at our institution over a 10-year period. Of these, 18 occurred in patients post autologous HCT (autoHCT), 23 in patients post allogeneic HCT (alloHCT). In the same time period, an additional 23 diagnoses were made in patients who had never undergone HCT. LGL expansion appeared an average of 485 days (range 30 – 1935 d) from alloHCT. In most patients, this occurred as an isolated finding, while in 5 patients, the clonal expansion was detectable on serial evaluations over a period of months or years (75 – 1662 d). LGL expansion was detected an average of 133 days from auto HCT, and only one patient had detectable clonal expansion over a prolonged period of time (70d). AutoHCT patients ranged from 23 to 72 years, average age 48.5 years. AlloHCT patients ranged from 26 to 62 years, average age 47.8 years. Incidence of reactivation of CMV postHCT was 56.5% in the alloHCT and 11% in the autoHCT. Relapse rates were 39% in the alloHCT and 28% in the autoHCT groups. At a median follow-up of 1372 days, 14 alloHCT patients remain in remission, with 9 relapses, and 5 deaths. At a median follow-up of 887 days, autoHCT patients remain in remission, with 5 relapses, and 3 deaths. Deaths were primarily attributed to relapse of disease and infectious complications, while no deaths were attributable to LGL clonal expansion. No patients with LGL clonal expansion have required treatment specifically for this condition.
43
Smith, Sonali M., Linda J. Burns, Koen van Besien, Jennifer LeRademacher, Wensheng He, Timothy S. Fenske, Ritsuro Suzuki, et al. "Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma." Journal of Clinical Oncology 31, no. 25 (September 1, 2013): 3100–3109. http://dx.doi.org/10.1200/jco.2012.46.0188.
Повний текст джерелаАнотація:
Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n = 115; median age, 43 years) or allogeneic HCT (alloHCT; n = 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes. Results AutoHCT recipients were more likely in first complete remission (CR1; 35% v 14%; P = .001) and with chemotherapy-sensitive disease (86% v 60%; P < .001), anaplastic large-cell histology (53% v 40%; P = .04), and two or fewer lines of prior therapy (65% v 44%; P < .001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42% and 53%, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31% remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95% CI, 1.80 to 6.99; P < .001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95% CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95% CI, 2.15 to 11.72) were prognostic of survival. Conclusion These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.
44
Vejarano, Rafael, Angel Henriuez, and Hector Montes. "Sistema para la interacción activa con autobuses de rutas urbanas de Panamá para personas con discapacidad visual." I+D Tecnológico 14, no. 2 (December 14, 2018): 17–23. http://dx.doi.org/10.33412/idt.v14.2.2069.
Повний текст джерелаАнотація:
El presente proyecto propone un sistema innovador que permite organizar un sistema de transporte inclusivo en las rutas urbanas en la República de Panamá, dirigido a mejorar la movilidad de las personas en situación de discapacidad visual, fomentando la integración social y mejorando la calidad de vida de este colectivo mediante el uso de la tecnología con iniciativas solidarias y activas. En este artículo se exponen las características principales de las aplicaciones ViDis y Bus, las cuales están diseñadas e implementadas por el grupo de investigación del proyecto MOVIDIS del Centro Regional en el Coclé de la Universidad Tecnológica de Panamá. Estas apps han sido desarrolladas para teléfonos inteligentes basados en Android, que proporcionan asistencia a personas con discapacidad visual para que puedan, en forma independiente, hacer uso del sistema de transporte público de pasajeros en Panamá. El sistema Bus informa a la persona con discapacidad visual sobre la ubicación del autobús y la distancia estimada de arribo al lugar donde esta persona se encuentra mediante comandos de voz y, adicionalmente, estando en el autobús, le proporciona información sobre las paradas durante el recorrido del autobús para que la solicite. Paralelamente, el sistema ViDis provee a la app Bus, la localización de la persona con discapacidad visual. De esta manera existe una interacción activa entre la persona con discapacidad visual y el conductor del autobús.
45
Di Modica, Giuseppe, Luca Evangelisti, Luca Foschini, Assimo Maris, and Sonia Melandri. "Testing the Scalability of the HS-AUTOFIT Tool in a High-Performance Computing Environment." Electronics 10, no. 18 (September 13, 2021): 2251. http://dx.doi.org/10.3390/electronics10182251.
Повний текст джерелаАнотація:
In the last years, the development of broadband chirped-pulse Fourier transform microwave spectrometers has revolutionized the field of rotational spectroscopy. Currently, it is possible to experimentally obtain a large quantity of spectra that would be difficult to analyze manually due to two main reasons. First, recent instruments allow obtaining a considerable amount of data in very short times, and second, it is possible to analyze complex mixtures of molecules that all contribute to the density of the spectra. AUTOFIT is a spectral assignment software application that was developed in 2013 to support and facilitate the analysis. Notwithstanding the benefits AUTOFIT brings in terms of automation of the analysis of the accumulated data, it still does not guarantee a good performance in terms of execution time because it leverages the computing power of a single computing machine. To cater to this requirement, we developed a parallel version of AUTOFIT, called HS-AUTOFIT, capable of running on high-performance computing (HPC) clusters to shorten the time to explore and analyze spectral big data. In this paper, we report some tests conducted on a real HPC cluster aimed at providing a quantitative assessment of HS-AUTOFIT’s scaling capabilities in a multi-node computing context. The collected results demonstrate the benefits of the proposed approach in terms of a significant reduction in computing time.
46
Rizky, Mohammad Rizkyanto, Aad Hariyadi, and Nugroho Suharto. "Design and Development of Wireless-Based Electric Load Control Monitoring System on Autobuses Vehicles." Jurnal Jartel Jurnal Jaringan Telekomunikasi 12, no. 4 (December 30, 2022): 270–75. http://dx.doi.org/10.33795/jartel.v12i4.508.
Повний текст джерелаАнотація:
The electrical installation structure on autobuses is generally still based on the old concept that relies on the fuse, where the fuse is the only safety as well as an indicator of the presence or absence of electrical power supply to several electrical devices contained in the autobus. For conditions where there is a short circuit on the line to the electrical load, the electrical equipment on the autobus cannot be operated again. With the problem in the electrical system on the autobus, a monitoring system for controlling the power used on the autobus vehicle was created automatically based on wireless. In this study, the system created using Arduino Uno is functioned as a server node. Then there is a sensor node which will later function to receive incoming data from the Ina219 sensor, then sent using wireless communication to the server node. Then on the server node, all data will be monitored via the LCD display and notification LED, then if there is excessive use the system will turn off the relay where the point is using excess power. From the test results, the sensor node is able to send data from the sensor node readings. Then it is sent to the Node Server and the results obtained are 2% for packet loss. The delay value is 0.29s for the highest result.
47
Czyz, Anna, Anna Lojko, Lidia Gil, Dominik Dytfeld, Danuta Drozdowska, Adam Nowicki, Maria Kozlowska, Krzysztof Sawinski, Jan Styczynski, and Mieczyslaw Komarnicki. "Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes." Blood 114, no. 22 (November 20, 2009): 3406. http://dx.doi.org/10.1182/blood.v114.22.3406.3406.
Повний текст джерелаАнотація:
Abstract Abstract 3406 Poster Board III-294 Autologous hematopoietic stem cell transplantation (autoHCT) is considered the treatment of choice for patients (pts) with relapsed Hodgkin's lymphoma (HL) and the treatment option for pts who did not adequately respond to conventional therapy. We retrospectively evaluated prognostic factors affecting the long-term outcome of 131 pts, median age 29 (16-59) years with advanced HL (stage IIB-IVB) treated with autoHCT following modified BEAM regimen (BCNU 300mg/m2, etoposid 800mg/m2, cytarabine 6000mg/m2, melphalan 140mg/m2 and dexamethasone 168mg/m2) between 1992 and 2007 in our department Twelve pts were treated with planned tandem autoHCT and received different regimen before second transplant. The indications for autoHCT were: inadequate response to conventional therapy defined as less then complete remission after first line chemotherapy (71 pts), relapse (52 pts) and progressive disease (8 pts). The patients were treated with the median 2.5 (range 1-4) chemotherapy lines before autoHCT. The disease status at transplant was: complete remission (47 pts), partial remission (73 pts) and less then PR (11 pts). The source of progenitor cells was bone marrow (46 pts), peripheral blood (76 pts) and bone marrow plus peripheral blood (9 pts). The median follow-up of the living patients was 65 (12-196) months. OS was 81% (95% CI 61-100), 52% (95% CI 26-78) and 43% (95% CI 6-84) at 7 years for patients transplanted due to inadequate response to conventional therapy, relapse and progressive disease respectively estimated with the Kaplan-Meier method. The 7-yrs DFS was 66% (95% CI 42-90), 56% (95% CI 5-67) and 50% (95% CI 15-84) for the same groups of pts respectively. There were 8/143 (5,6 %) early deaths due to infection (7 pts) and primary graft failure (1 patient). The secondary malignancies developed in 5 pts, including 3 cases of MDS/AML, 1 case of NHL and one solid tumor. The 10-year cumulative incidence of secondary malignancies was 9%. In univariate analysis, prognostic factors associated with decreased DFS and OS of the pts transplanted due to relapse were the disease status at transplantation (less then PR vs CR/PR, p 0.01) and the duration of initial remission (< 12 months vs > 12 months, p 0.01 for OS and p 0.003 for DFS). In multivariate analysis, the disease status at autoHCT remained statistically significant (HR 1.69, p 0.05) for OS and the duration of initial remission (HR 8.9, p 0.04) for DFS. DFS of pts transplanted due to inadequate response to conventional therapy or progressive disease was adversely affected by the number of prior chemotherapy lines (>2 vs 1-2 lines, HR 6.0, p 0.05). We conclude that high proportion of patients with advanced HL who did not adequately respond to conventional treatment can be cured with autoHCT following modified BEAM regimen performed early in the course of the disease. The outcome of pts with relapsed disease depends on the response to the salvage therapy. The results of autoHCT in chemoresistant relapse are not satisfactory. Disclosures: No relevant conflicts of interest to declare.
48
Gada, Purvi, Todd Defor, Daniel J. Weisdorf, Jeffrey S. Miller, Paul J. Orchard, Margaret L. MacMillan, Mukta Arora, Marcie Tomblyn, and Linda J. Burns. "Prolonged Remissions with Autologous and Allogeneic Stem Cell Transplantation for Burkitt’s Lymphoma: Long Term Follow-Up at a Single Institution." Blood 106, no. 11 (November 16, 2005): 1133. http://dx.doi.org/10.1182/blood.v106.11.1133.1133.
Повний текст джерелаАнотація:
Abstract Burkitts Lymphoma (BL) is a highly aggressive form of non-Hodgkins lymphoma (NHL) that accounts for 50% of childhood cases of NHL, yet is rare in adults. B symptoms, advanced stage and extranodal disease are risk factors previously associated with poor survival. Hematopoietic stem cell transplantation (HCT) is often used because of either incomplete or short duration of remission with standard therapy yet little published data for HCT and BL exists. We evaluated the comparative safety and efficacy of a cyclophosphamide/total body irradiation-containing myeloablative conditioning regimen followed by either an autologous HCT (autoHCT) or allogeneic related donor HCT (alloHCT) in 38 patients who received transplants between October 1975 and June 2004. Twenty-five patients (median age 16 years [range, 4–65]) underwent an autoHCT; 13 patients (median age 13 [range, 4–62]) received an alloHCT. The median number of conventional chemotherapy regimens prior to transplant was 2 (range 1–4); the median duration of first complete remission (CR) was 0.4 years (range, 0–8.8). The majority of patients were in a complete remission (CR) at transplant (auto HCT - 16 [64%] [40% CR1]), alloHCT - 9 [69%] [23% CR1]). Patient demographics, disease characteristics at diagnosis, at relapse and at transplant were comparable between the two groups except for a greater incidence of high risk factors, including B symptoms, advanced stage at diagnosis, and extranodal (bone marrow and central nervous system) disease in the alloHCT group. The median follow up is 7 years (range 1–12) and 24 years (range 2–27) for the autoHCT and alloHCT groups, respectively. Post-transplant, 71% of auto-HCT and 75% of the alloHCT recipients obtained a CR. The 1-year treatment related mortality (TRM) was comparable in the two groups: 8% and 15% for the autoHCT and alloHCT groups, respectively (p=NS). Ten-year progression free survival (PFS) was 21% (95% CI, 4–38%) and overall survival (OS) 23% (95% CI, 5–41%) after autoHCT compared to 31% (95% CI, 6–66%) and 31% (95% CI, 6–66%) for alloHCT (p=NS). Six patients in autoHCT group and 3 in alloHCT survive disease free between 1 and 27 years; 5 survive beyond 10 years and 3 beyond 15 years from HCT. Donor choice did not significantly alter PFS. Two factors were predictive of superior PFS: fewer chemotherapy regimens prior to transplantation (1 vs ≥ 2) and CR (vs relapsed/persistent disease) at time of transplant. Patients with high risk factors more commonly underwent alloHCT, yet outcomes were comparable to autoHCT, suggesting that a powerful and durable graft versus lymphoma effect exists. These results demonstrate that prolonged remissions can be obtained with either auto or alloHCT, especially for high risk patients in CR. New approaches for patients in relapse are needed to improve these outcomes.
49
Hunter, Bradley, Ben Rosen, Miguel Castillo, Lawrence D. Kaplan, Weiyun Z. Ai, Lloyd E. Damon, Thomas G. Martin, and Charalambos Andreadis. "Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)." Blood 128, no. 22 (December 2, 2016): 4638. http://dx.doi.org/10.1182/blood.v128.22.4638.4638.
Повний текст джерелаАнотація:
Abstract Introduction: For patients with relapsed or refractory DLBCL with chemosensitive disease after 2nd line (salvage treatment), AutoHCT is considered the standard of care. Risk factors for progression following AutoHCT include primary refractory disease and early relapse (<12 months after initial chemotherapy. In our institution, we have previously shown that a course of ICT given prior to AutoHCT in patients with these high-risk features results in improved outcomes in DLBCL and other lymphomas (Damon et al, BMT 2008; 42(10):649-57). More recently, cell of origin (COO) subtype and double myc and bcl2 protein expression (DPP) status have been shown to predict outcome to front line treatment but data in the relapsed setting are lacking. We hypothesized that our approach of ICT followed by AutoHCT will increase the likelihood of complete remission (especially in patients with high-risk clinical or biologic features) and improve progression free survival (PFS) following AutoHCT. Methods: Consecutive patients who underwent ICT followed by autoHCT for relapsed/refractory DLBCL at our institution between 2005-2015 and had available tissue samples for review were included in our analysis. ICT was applied per institutional standard to patients with apriori identified high-risk features as described below. This chemotherapy step is utilized for stem cell mobilization following evidence of chemosensitivity and prior to undergoing AutoHCT. COO was determined using the Hans algorithm and DPP status using the Johnson criteria. Following CHR approval, patient's charts and EMR were reviewed to ascertain baseline variables and outcome data. Response was determined using radiologic (CT) and metabolic (PET) imaging for all patients at the time of transplantation. Survival probability was estimated by the Kaplan-Meier method. Comparisons were made using the X2 test and Fisher's exact test, where appropriate. Results: A total of 35 patients were included in this analysis. Out of those, 30 patients received a high-dose etoposide and ara-C-based ICT regimen as described by Damon et al. 13/30 (43.3%) were female, 17/30 (56.7%) were male. Median age at transplant was 56 (range 34-68). The high risk features that lead to this treatment were: early (<12 months) relapse (9/30, 30%) or refractory disease (13/30, 43.3%)to front line therapy or other (8/30, 27.7%). In all, 16/30 (53%) patients achieved CR at the end of salvage therapy, with this proportion increasing to 26/30 (86.7%) CR after ICT. Eventually, 24/30 (80%) of patients were able to continue on to AutoHCT, 23/30 (76.7%) with CBV, 4/30 (13.3%) with BEAM, and 3/10 (10.0%) other. With a median follow up of 20 months, 66% of patients are progression-free at 24 months (Figure 1). In our cohort, 8/30 (27%) were germinal center B-cell origin subtype (GCB), 19/30 (63.3%) were non-GCB subtype and 3 (10.0%) could not be identified. In all, 8/30 (26.7%) were double protein positive, 18 (60.0% were double protein negative and 4 (13.3%) could not be determined. Notably, 15.8% of patients with non-GCB were double protein expressors, compared to 37.5% of patients with GCB (Fisher's exact p=0.06). Neither COO nor DPP were associated with response rates prior to AutoHCT (p=0.6 and p=0.17 respectively) or with PFS (p=0.32 and p=0.72 respectively and Figures 2a and 2b). Conclusions: Even though COO and DPP status are associated with inferior outcomes in the front-line setting of patients with DLBCL, data in the relapsed setting are limited. In a cohort of high-risk patients with relapsed DLBCL, we confirmed our previously described excellent outcomes with ICT in terms of increased CR rates prior to AutoHCT and a high rate of 2-year PFS. Moreover, while numbers are small, our study suggests that ICT leads to similar outcomes regardless of cell of origin or double protein expression status. Figure 1 PFS among Patients with Intensive Consolidation Figure 1. PFS among Patients with Intensive Consolidation Figure 2 PFS by cell of origin p=0.32 Figure 2. PFS by cell of origin. / p=0.32 Figure 3 PFS by Double Protein Expression Status p=0.72 Figure 3. PFS by Double Protein Expression Status. / p=0.72 Disclosures Martin: Amgen: Research Funding; Sanofi: Research Funding.
50
Riedell, Peter A., Mehdi Hamadani, Kwang Woo Ahn, Carlos Litovich, Mohamed Kharfan-Dabaja, Alex Francisco Herrera, Craig Steven Sauter, and Sonali M. Smith. "Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 7521. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7521.
Повний текст джерелаАнотація:
7521 Background: In MCL, outcomes are heterogeneous and the clinical significance of the timing of relapse following autoHCT and its impact on OS is not well defined. Using the CIBMTR database, we evaluate the effect of post-autoHCT time to relapse on OS over time. Methods: Adult MCL pts treated with up to two lines of rituximab-based induction therapy followed by first autoHCT within 1-year of diagnosis were identified between 2000-2018. Primary outcomes included OS and post-relapse OS. A dynamic landmark analysis was performed at 6-month intervals following autoHCT to evaluate the impact of relapse on OS while adjusting for significant patient- and disease-related variables. Post-relapse OS was evaluated in pts who experienced relapse. Results: Of the 461 pts included in the analysis, the median age was 60 years (range 29-78), 57% had a KPS of ≥ 90, 83% had stage III-IV disease at diagnosis, and 76% had extranodal involvement. BEAM was the most common conditioning regimen (58%) and 23% of pts received post-autoHCT maintenance rituximab. With a median follow-up of 67 months, the 5-year progression-free survival was 45.8% with a 5-year OS of 69.6%. On multivariate analysis, age ≥60 years was associated with worse OS (HR= 1.55, 95% CI 1.08-2.24, p=0.0191) at all landmark timepoints. Additionally, the impact of relapse on OS varied with time (p=0.006) and was greatest at the 6-month (HR=7.68), 12-month (HR=6.68), and 18-month (HR=5.81) landmark timepoints. The risk of death for relapsing pts decreased with time and was mirrored by an improvement in adjusted OS for both relapsing and non-relapsing pts. In total, 9.3% of patients relapsed prior to the 18-month landmark timepoint. Relapse at the 6-month, 12-month, and 18-month landmark timepoints correlated with a poor median post-relapse OS of 9 months, 24 months, and 34 months, respectively (Table). Conversely, patients relapsing after the 18-month landmark timepoint experienced a median post-relapse OS ranging from 44-67 months. Conclusions: In MCL, early relapse (< 18-months) following autoHCT defines a high-risk group with inferior post-relapse OS. This population should be considered for clinical trials or novel therapeutic approaches including early utilization of chimeric antigen receptor T-cell therapy.[Table: see text]